CSPC Group (01093): Phase I clinical trial of SYS6057 (recombinant respiratory syncytial virus vaccine (CHO cells)) officially launched in China

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shiyao Group (01093) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.

This product is a recombinant RSV vaccine (CHO cells) developed by the Group. It is clinically intended to prevent lower respiratory diseases caused by RSV infection. Pre-clinical pharmacodynamics, pharmacokinetics, and toxicology studies have been fully completed. Research results show that the product has a good anti-drug protection effect on both RSV A and B subtypes, shows high neutralizing antibody activity, and has a long-lasting immune protection effect.

The Group received the “Drug Clinical Trial Approval Notice” issued by the China Drug Administration in July 2026, and initiated a randomized, blinded, placebo-controlled phase I clinical trial after approval to evaluate the safety and immunogenicity of this product in people aged 18 and above. Currently, the recruitment and screening of participants for this clinical trial is being actively promoted.